Our Office
Media Center
Divisions
Resources
Initiatives
Mortgage Settlement
I-STOP
Conviction Review Bureau
Taxpayer Protection
Religious Rights
Immigration Services Fraud
Debt Settlement & Collection
Pennies for Charity
NY Open Government
Free Educational Programs
Medicaid Fraud Control Unit
Animal Protection
Charity Disclosure Regulations
Homeowner Protection Program
Human Trafficking
Contact Us
Search
Statement Regarding A Decision By Glaxosmithkline To Release Paxil Clinical Data
Attorney General Spitzer today issued the following statement in response to a decision by GlaxoSmithKline to release clinical data regarding the safety and effectiveness of its antidepressant drug Paxil. Spitzer sued the company on June 2 alleging that the company misled doctors about the drug.
"This is a positive first step toward changing a dangerous industry practice. We can no longer permit GSK and other pharmaceutical companies to selectively choose what research to make available to physicians and the public. It is unacceptable for companies like GSK to divulge favorable results while hiding negative data when the health of patients is at stake. While today's development by GSK does not resolve all of the issues in our litigation it does represent movement in the right direction."